Copyright © Inderes 2011 - present. All rights reserved.

Nexstim

9.00 EUR

+1.01 %

5,643 following
Corporate customer

NXTMH

First North Finland

Medical Equipment & Services

Health Care

+1.01 %
+1.81 %
-27.13 %
-36.62 %
-45.12 %
+11.11 %
+145.23 %
+28.94 %
-98.51 %

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more
Market cap
64.92M EUR
Turnover
21.84K EUR
P/E (adj.) (26e)
64.13
EV/EBIT (adj.) (26e)
55.88
P/B (26e)
12.43
EV/S (26e)
5.31
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
11.50 EUR
Updated
26.02.2026
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 27.02.2026

Latest extensive report

Released: 26.06.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
14.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
I was there! Nothing “new” came to light. The CEO gave a convincing overview and also presented the new NBS 6 device in the showroom. The buns were big, and things are generally baking well for the company .
3/30/2026, 5:36 PM
by Tomi Lindell
46
nexstim.com Nexstim - Nexstimin suurimmat osakkeenomistajat It seems even professionals are slowly finding their way here. Gerako Oy has risen to 75th place on the list. Gerako has shown good business acumen in the past, for example, achieving a 1700% return from Revenio. Arvopaperi...
4/1/2026, 7:40 AM
by Kyhnykeisari
32
In an episode of the Yle Areena series “Elossa” (Alive), 63-year-old Teresa shares her experiences with chronic neuropathic pain. She suffers from CRPS II pain (complex regional pain syndrome), which began after a surgical complication. Teresa has lived with continuous, widespread...
4/14/2026, 11:18 AM
by Kyhnykeisari
29
Brainsway’s market value has already surpassed 600 million dollars. The market seems to highly value a profitably growing TMS company, but there are still less valued options available for interested buyers. Brainsway also released a press release yesterday stating that in the US...
8 hours ago
by Kyhnykeisari
24
@Antti_Siltanen had made a good overview of the number of TMS studies. The number of studies has been growing well, and surely some of them will also translate into demand for clinical devices with a delay. Inderes – 10 Apr 26 TMS-laitteistojen käyttö tutkimuksessa - Inderes TMS:...
4/10/2026, 5:58 AM
by Kyhnykeisari
23
Neuronetics’ CEO and CFO have both left within a short period. The company has also been incurring massive losses for a long time, so I wouldn’t be surprised if the company’s end is near. This could potentially improve Nexstim’s competitive position, especially in the US therapy ...
4/8/2026, 5:15 AM
by Kyhnykeisari
20
An interesting Alz article from Christin Glorioso. Christin represents a newer way of thinking in Alz research, where prevention is also a goal. The article gives a quick glance at where we are with new drug therapies, and where we are with various device therapies (these are in ...
4/14/2026, 6:59 AM
by AccionHombre
18
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.